Humira takes over ‘uveitis’ as well with versatility

Published: 2017-11-13 16:27:00
Updated: 2017-11-13 16:03:58

‘Humira(generic name: adalimumab),’ the most well-known TNF(tumor necrosis factor)-α inhibitor and a chronic immune disorder treatment having 14 Korean indications in Korea, has attracted attention of the industry as recently getting the health insurance benefit on intractable non-infectious uvei...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.